var data={"title":"Calcium polystyrene sulfonate (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcium polystyrene sulfonate (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/46501?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcium-polystyrene-sulfonate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcium polystyrene sulfonate (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646930\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Resonium Calcium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646932\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647025\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hyperkalemia:</b> Initiate treatment if potassium level &gt;6 mmol/L (6 mEq/L); discontinue when potassium &le;5 mmol/L (5 mEq/L).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Usual dose: 15 g 3 to 4 times daily; dose should be based on clinical presentation and serum electrolyte levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: 30 g once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647024\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hyperkalemia:</b> Initiate treatment if potassium level &gt;6 mmol/L (6 mEq/L); discontinue when potassium &le;5 mmol/L (5 mEq/L). In small children and infants, employ lower doses by using the practical exchange ratio of 1 mEq potassium per gram of resin as the basis for calculation.</p>\n    <p style=\"text-indent:0em;\">Neonates: Rectal: 0.5 to 1 g/kg/dose</p>\n    <p style=\"text-indent:0em;\">Children:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Oral (preferred route): Initial: 1 g/kg daily in divided doses; Maintenance: May reduce dose to 0.5 g/kg daily in divided doses</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Rectal: Initial: 1 g/kg daily in divided doses; Maintenance: May reduce dose to 0.5 g/kg daily in divided doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647026\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48963116\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, dosage adjustments may be necessary based on changes in serum potassium and/or calcium levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48963117\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10076207\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for suspension, oral/rectal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Resonium Calcium: 300 g [contains calcium 1.6 to 2.4 mmol/g, sodium &lt;1 mg/g; packaging contains 15 g measuring device]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217371\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647027\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer orally (via nasogastric tube if unable to swallow) as a prepared suspension or paste. Patient should be positioned carefully during ingestion to avoid aspiration.<b> Note:</b> More rapid lowering of potassium may be achieved with concomitant oral and rectal administration. Rectal route may be discontinued once orally administered resin has reached rectum. Oral administration in neonates is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Enema route is less effective than oral administration. Administer rectally as a prepared suspension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enema should be retained as long as possible (product labeling suggests for at least 9 hours in adults or as long as possible) as greater amounts of potassium are excreted as retention time increases. Follow enema with irrigation to remove resin.<b> Note: </b>More rapid lowering of potassium may be achieved with concomitant oral and rectal administration. Rectal route may be discontinued once orally administered resin has reached rectum.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646933\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia: </b>Treatment of hyperkalemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646928\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calcium polystyrene sulfonate may be confused with sodium polystyrene sulfonate</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646964\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, constipation, diarrhea, gastric irritation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Acute bronchitis, bronchopneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: Bezoar formation (oral administration), fecal impaction (rectal administration), gastrointestinal necrosis, gastrointestinal obstruction (rare), gastrointestinal ulcer, hypercalcemia, hypomagnesemia, intestinal stenosis, ischemic colitis, mesenteric ischemia, rectal hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646937\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to polystyrene sulfonate resins or any component of the formulation; potassium &lt;5 mmol/L (5 mEq/L); conditions associated with hypercalcemia (eg, metastatic carcinoma, multiple myeloma, hyperparathyroidism, or sarcoidosis); obstructive bowel disease; oral administration in neonates; use in neonates with reduced gut motility (postoperative, drug induced)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646938\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte disturbances: Use may be associated with electrolyte disturbances including hypokalemia, hypercalcemia, and/or hypomagnesemia. Closely monitor electrolytes during therapy. Discontinue use if potassium &le;5 mmol/L (5 mEq/L).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Gastrointestinal stenosis, intestinal ischemia, ischemic colitis, rectal hemorrhage, gastrointestinal necrosis, and intestinal perforation with fatal outcomes have been reported, particularly in patients with underlying risk factors (eg, prematurity, history of intestinal disease or surgery, renal impairment, hypovolemia, severe burn, immunosuppressive therapy).  Fecal impaction with rectal administration and concretion formation with oral administration have also occurred. Effects may be related to use of sorbitol enema with inadequate/absence of lavage after resin use. Avoid excess dosing or inadequate dilution with rectal administration to avoid resin impaction. Discontinue use in patients with clinically significant constipation. Intermittent therapy may be considered for patients developing nausea/vomiting, diarrhea, gastric irritation and anorexia, and the use of mild laxatives may be considered if constipation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in renal impairment and/or dialysis patients. Sudden increases in calcium may be observed; monitor calcium weekly (or more frequently if clinically indicated). Dosage adjustments may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates/infants: Oral administration is contraindicated in neonates. Use caution with rectal administration to avoid resin impaction. Premature/low-birth-weight infants may be at risk for GI hemorrhage or colonic necrosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298944\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9655296\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8498&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Calcium Polystyrene Sulfonate may enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction.  Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin. Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Calcium Polystyrene Sulfonate may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Laxatives (Magnesium Containing): May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis. Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Calcium Polystyrene Sulfonate may decrease the serum concentration of Lithium.  Management: Consider separating administration of lithium from administration of oral calcium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meloxicam: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sorbitol: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Calcium Polystyrene Sulfonate may decrease the serum concentration of Thyroid Products.  Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646934\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Does not undergo gastrointestinal (GI) absorption. There are no adequate and well-controlled studies in pregnant women. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13333891\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Does not undergo GI absorption</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646977\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May administer orally with honey, jam, or liquids with low potassium content. Do <b>not</b> mix in fruit juices (eg, orange juice) or other beverages with high potassium content. Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647036\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Close monitoring of serum electrolytes (potassium, sodium, calcium, magnesium); ECG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647035\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum potassium: Adults: 3.5 to 5.2 mEq/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9647033\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Removes potassium by exchanging calcium ions for potassium ions in the intestine before the resin is excreted from the body</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9646972\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: May be delayed 1 to 2 days due to GI transit time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (100%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059485\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Argamate (KR);</li>\n      <li>Cal-Bind (LK);</li>\n      <li>Calcium Resonium (AU, HK, IE, IN, KW, MT, PL, QA, SA);</li>\n      <li>Calcuim Resonium (CN);</li>\n      <li>Kalimate (JP, MY, PH, TH, TW);</li>\n      <li>Kalitake (ID);</li>\n      <li>Kalitaker (KR);</li>\n      <li>Kalquest (ID);</li>\n      <li>Kinelene (TH);</li>\n      <li>Less-K (TH);</li>\n      <li>Resical (CZ, HU, PT);</li>\n      <li>Resikali (FR);</li>\n      <li>Resincalcio (AR, MY, TH);</li>\n      <li>Resonium (VN);</li>\n      <li>Sorbisterit (AT, BE, CH, CL, DE, DK, EE, ES, FI, GB, LT, LU, NL, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Resonium Calcium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec, Canada: Sanofi Aventis Canada Inc; July 2014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-drug-information/abstract-text/19751641/pubmed\" target=\"_blank\" id=\"19751641\">19751641</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8498 Version 75.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9646930\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9646932\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9647025\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9647024\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9647026\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F48963116\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F48963117\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10076207\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11217371\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9647027\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9646933\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9646928\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9646964\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9646937\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9646938\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298944\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9655296\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9646934\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13333891\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9646977\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9647036\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F9647035\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9647033\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9646972\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059485\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8498|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcium-polystyrene-sulfonate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Calcium polystyrene sulfonate (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}